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Abstract
Background: The aim of this study was to evaluate the effect of MetS on arterial stiffness in a longitudinal study.
Methods: Brachial-ankle pulse wave velocity (baPWV), a measurement interpreted as arterial stiffness, was
measured in 1518 community-dwelling persons at baseline and re-examined within a mean follow-up period of 3
years. Multivariate linear regression with generalized estimating equations (GEE) were used to examine the
longitudinal relationship between MetS and its individual components and baPWV, while multivariate logistic
regression with GEE was used to examine the longitudinal relationship between MetS and its individual
components and the high risk group with arterial stiffness.
Results: Subjects with MetS showed significantly greater baPWV at the end point than those without MetS, after
adjusting for age, gender, education, hypertension medication and mean arterial pressure (MAP). MetS was associated
with the top quartile of baPWV (the high-risk group of arterial stiffness, adjusted odds ratio [95% confidence interval]
1.52 [1.21-1.90]), and a significant linear trend of risk for the number of components of MetS was found (p for trend <
0.05). In further considering the individual MetS component, elevated blood pressure and fasting glucose significantly
predicted a high risk of arterial stiffness (adjusted OR [95% CI] 3.72 [2.81-4.93] and 1.35 [1.08-1.68], respectively).
Conclusions: MetS affects the subject’s progression to arterial stiffness. Arterial stiffness increased as the number of MetS
components increased. Management of MetS is important for preventing the progression to advanced arterial stiffness.
Keywords: metabolic syndrome, pulse wave velocity, arterial stiffness
Background
Metabolic syndrome (MetS), defined as a cluster of fea-
tures such as visceral obesity, impaired glucose tolerance,
dyslipidemia, hypergtriglyceridemia, and elevated blood
pressure [1,2], is highly prevalent all over the world
[3-12]. MetS has been known as a critical risk factor in
the incidence of type 2 diabetes and in cardiovascular
outcome [1,13,14]. People with MetS have higher all-
cause or cardiovascular mortality than those without
MetS [15-17]. Arterial stiffness, a pathological condition
with vascular damage, is a cardiovascular outcome of
MetS. In clinical practice, pulse wave velocity (PWV) is
widely used to reflect arterial stiffness. A noninvasive
b r a c h i a l - a n k l ep u l s ew a v ev elocity (baPWV) measure-
ment, which is performed more easily than carotid-
femoral PWV measurement, has been used as a marker
for screening vascular damage and cardiovascular risk in
the general population [18,19], in diabetes patients
[20,21], in hypertension patients [22,23], in patients with
end-stage renal disease [24,25], and in women with
systemic lupus erythematosus [26].
The association of MetS with arterial stiffness has been
investigated in many studies [27-31]; however, most of
these studies were cross-sectional [27-29,31] Studies
explored the longitudinal effect of MetS on arterial
stiffeness in specific subject s ,s u c ha sp a t i e n t sw h ow e r e
systemic lupus erythematosus [32], patients who were
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sons who received work-related health check-up [34] or
general health check-up [35]. None of them was commu-
nity-based study. One study reported a longitudinal rela-
tion between PWV and MetS only in men workers [34].
Another 6-year follow-up study perfomed by Safar et al
explored this relationship in subjects selected from
receiving general health check-up population with preva-
lence of elevated blood pressure of 50% [35]. Moreover,
high prevalence of diabetes and dyslipidemia in the study
by Safar et al was found. It is very likely to have Berkson’s
bias in their study [36]. Previous study showed the asso-
ciation may be found significantly in clinical-based stu-
dies, but not in community-based studies [37]. Our study
is the first community-based study using the probability
sampling method to select a random sample from a well-
defined population. Identifying the effect of MetS on
arterial stiffness using a longitudinal study in a commu-
nity-based population can provide information for the
management of MetS and thereby prevent progression to
advanced arterial vascular disease. Therefore, the objec-
tive of the current study was to evaluate the longitudinal
effect of MetS on baPWV by considering mean arterial
pressure (MAP) and the use of hypertension medicine to
reduce the influence of blood pressure on baPWV.
Methods
Study sample
This was a population-based follow-up study. The design
and selection criteria of the Taichung Community Health
Study (TCHS) have been described previously [4]. Briefly,
4, 280 individuals were randomly selected from Taichung
City, Taiwan to be representative of its residents in terms
of sex and age (aged 40 and over). Data on 2, 359 indivi-
duals (about 66.83% of the original sample) were collected
from 2004-2005, and 2, 311 survivors were contacted 3
years later for re-examination. A total of 1, 648 subjects
were followed (overall follow-up rate, 71.3%) before the
end of July, 2009. Of those, 28 were excluded from this
analysis because they did not have a baPWV measurement
at baseline or follow-up, 100 were excluded because they
had suspected peripheral arterial stiffness (ankle-brachial
index < 0.9 at baseline), and 2 were excluded because of
missing smoking status at baseline. In the end, 1, 518 indi-
viduals (mean age, 56 years; 49% women) remained eligi-
ble for data analysis. All subjects signed an informed
consent form before data collection.
Measurements
Anthropometric measurements and laboratory
examination
All study subjects underwent a physical examination
measuring height, waist circumference (WC), and blood
pressure by trained staff at baseline, as well as at the
endpoint. MAP was calculated as (2 ×diastolic blood
pressure + systolic blood pressure) ÷ 3. Blood was drawn
with minimal trauma from an antecubital vein in the
morning, after a 12-hour overnight fasting, and was sent
for analysis within four hours of collection. Biochemical
markers such as HDL cholesterol, triglyceride, and fast-
ing glucose were analyzed by a biochemical autoanalyzer
(Beckman Coluter, Lx-20, USA) at the Clinical Labora-
tory Department of China Medical University Hospital.
Sociodemographic factors, lifestyle factors and medical
history
Data on sociodemographic factors (including age, gender
and education), lifestyle factors, and medical history were
collected by self-administered questionnaires. Lifestyle
factors, such as smoking and alcohol drinking history,
were categorized as never and former/current. We col-
lected self-reported personal medical histories, including
diabetes and hypertension medication at the baseline and
follow-up examination.
MetS and its components
MetS was defined clinically, based on the presence of
three or more of the following American Heart Associa-
tion and the National Heart Lung Blood Institute(AHA/
NHLBI) MetS criteria [2]: (1) central obesity (WC ≥ 90
cm in men, and
380 cm in women), (2) high triglycerides
level (
31.7 mmol/L or on drug treatment for elevated tri-
glycerides), (3) low HDL-C level (< 1.03 mmol/L in men
and < 1.30 mmol/L in women or on drug treatment for
reduced HDL-C), (4) high blood pressure (systolic BP
3130 mmHg or diastolic BP
385 mmHg or under anti-
hypertensive drug treatment in a patient with a history of
hypertension), and (5) high fasting plasma glucose con-
centration (
35.5 mmol/L or on drug treatment for ele-
vated glucose). Diabetes was defined as fasting plasma
glucose concentration
37.0 mmol/L or on drug treatment
for diabetes. Hypertension was defined as systolic BP
3140 mmHg or diastolic BP
390 mmHg or on drug treat-
ment for hypertension.
Longitudinal changes in arterial stiffness
BaPWV, presenting for arterial stiffness, was measured
non-invasively with subjects in the supine position and
with a VP-1000 automated PWV/ABI analyzer (PWV/
ABI; Colin Co. Ltd., Komaki, Japan) attached to the four
limbs [38]. For every subject, the maximum of the left
and right baPWV was chosen at baseline and at follow-
up. The change in baPWV was calculated as re-examined
baPWV subtracting baseline baPWV.
Statistical analysis
Continuous variables were reported as mean ± standard
deviation (SD) and categorical variables were reported
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CI). The variables that predicted the baPWV change
were evaluated by analysis of covariate with baPWV at
baseline as covariate due to its high impact on the
baPWV change. Moreover, to explore the effect of MetS
and its components on baPWV, three multivariate mod-
els were used. First, the longitudinal effect of MetS and
the number of components on the change baPWV at
follow-up were examined using multivariate linear
regression with the generalized estimating equations
(GEE) method. Second, we further evaluated how the
longitudinal effect of individual MetS components on
baPWV was affected by the other components being
considered sequentially, using hierarchical linear regres-
sion analysis with the GEE approach. The order of
entering the variables was elevated blood pressure, fast-
ing glucose, WC, triglyceride, and low HDL cholesterol
after adjustment. Last, the top quartile of baseline
baPWV was used as the cutoff point to classify the high
risk group with arterial stiffness. Multivariate logistic
regression with the GEE approach was used to analyze
the longitudinal effect of MetS and its components on
arterial stiffness. We treated the number of MetS com-
ponents as continuous variables to examine the linear
trend on the risk of arterial stiffness. All reported p
values were those of the two-sided tests; statistical sig-
nificance was set at p < 0.05. All analyses were per-
formed using SAS version 9.1 (SAS Institute Inc, Cary,
NC).
Results
Compared with individuals without MetS, a higher pro-
portion of individuals with MetS were older, male, with ≤
9 years of educational attainment, former or current smo-
kers, former or current drinkers, and users of hyperten-
sion, hyperlipidemia, and diabetes medication (Table 1).
The baseline baPWV and changes in baPWV during the
follow-up period, according to the various groups of socio-
demographic factors, health factors, and medication after
adjusting for baPWV at baseline, are illustrated in Table 2.
Larger increases in changes of baPWV were observed in
those with an older age, lower educational level, and use
of medication for hypertension, hyperlipidemia, and dia-
betes at baseline (all p < 0.05). The changes were not sig-
nificantly different in terms of marital status and health
factors at baseline, such as smoking and drinking.
Subjects with MetS had a higher mean value of
baPWV at baseline. Compared to subjects without
MetS, subjects with MetS had a significantly greater 3-
year mean change of baPWV (-9.5 vs. 31.1, after adjust-
ing for baPWV at baseline) (Table 3). The greater the
number of MetS components at baseline, the larger the
adjusted mean changes of baPWV (p for trend < 0.001).
Analysis of the longitudinal effect of MetS on baPWV
using GEE models showed that subjects with MetS had a
h i g h e rm e a nb a P W Vo f3 6 . 2( p < 0.001) after adjusting
for age, gender, education, smoke status, time-dependent
hypertension medication, and time-dependent MAP
(Figure 1). Considering the longitudinal effect of the
number of MetS components on baPWV, the differences
in baPWV in subjects with 1, 2 and more than or equal to
3 MetS components versus those without a MetS compo-
nent were 38.2, 46.7 and 76.3, respectively (all p < 0.001)
(Figure 1).
In exploring the independent effects of MetS compo-
nents, hierarchical regression analysis with the GEE
approach demonstrated that elevated blood pressure
(adjusted regression coefficients [b] = 28.3, p <0 . 0 5 )
and fasting glucose (b = 51.4, p < 0.001) had an inde-
pendent effect on longitudinal baPWV (Table 4).
Table 1 Baseline characteristics of subjects with and
without metabolic syndrome
Non-MetS
† MetS
†
Variable at baseline n (%) n (%) p value
Sociodemographic factors
Age < 0.001
40-50 years 372 (39.2) 128 (22.5)
51-60 years 335 (35.3) 187 (32.9)
61-70 years 151 (15.9) 140 (24.7)
> 70 years 92 (9.6) 113 (19.9)
Gender < 0.001
Female 521 (54.8) 227 (40.0)
Male 429 (45.2) 341 (60.0)
Education < 0.001
≤ 9 years 268 (28.3) 231 (40.7)
10-12 years 471 (49.7) 256 (45.2)
> 12 years 208 (22.0) 80 (14.1)
Married status 0.691
Not currently married 154 (16.3) 87 (15.4)
Married 790 (83.7) 478 (84.6)
Lifestyle factors
Smoking < 0.001
Never 744 (78.3) 377 (66.4)
Former/Current 206 (21.7) 191 (33.6)
Drinking 0.008
Never 691 (72.7) 376 (66.2)
Former/Current 259 (27.3) 192 (33.8)
Medication
Hypertension
Yes 139 (14.6) 265 (46.7) < 0.001
Hyperlipidemia
Yes 51 (5.4) 132 (23.2) < 0.001
Diabetes
Yes 20 (2.1) 103 (18.1) < 0.001
† MetS, metabolic syndrome
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Page 3 of 8Table 2 Brachial-ankle pulse wave velocity (baPWV) at baseline and its changes adjusted for baPWV at baseline
during the period of follow-up of baseline characteristics
baPWV at baseline Changes of baPWV during follow-up period*
Variable at baseline n Mean ± SD Adjusted mean ± SE p value
Sociodemographic factors
Age < 0.001
40-50 years 500 1365.1 ± 212.7 -62.6 ± 10.8
51-60 years 522 1552.2 ± 281.5 -18.4 ± 9.6
61-70 years 291 1789.3 ± 366.2 70.9 ± 13.2
> 70 years 205 2147.2 ± 459.2 141.0 ± 18.1
Gender 0.101
Female 770 1674.4 ± 397.6 -3.8 ± 8.3
Male 748 1556.6 ± 399.3 14.9 ± 8.2
Education 0.004
≤ 9 years 499 1736.7 ± 443.3 34.3 ± 10.2
10-12 years 727 1566.5 ± 372.9 -6.7 ± 8.4
> 12 years 288 1532.1 ± 353.0 -10.3 ± 13.3
Married status 0.398
Not currently married 241 1660.5 ± 446.4 17.0 ± 14.6
Married 1268 1607.3 ± 393.3 3.6 ± 6.3
lifestyle factors
Smoking 0.346
Never 1121 1603.1 ± 415.1 2.4 ± 6.7
Former/Current 397 1653.9 ± 363.2 14.9 ± 11.3
Drinking 0.553
Never 1067 1623.6 ± 416.8 7.9 ± 6.9
Former/Current 451 1599.4 ± 367.0 0.4 ± 10.6
Medication
Hypertension < 0.001
No 1197 1541.9 ± 355.3 -8.6 ± 6.6
Yes 304 1903.1 ± 440.7 68.8 ± 13.6
Hyperlipidemia 0.002
No 1401 1604.9 ± 397.8 1.3 ± 6.0
Yes 93 1779.7 ± 397.3 77.7 ± 23.3
Diabetes < 0.001
No 1415 1591.3 ± 382.0 -3.8 ± 5.9
Yes 94 1997.6 ± 476.7 146.7 ± 23.7
SD, standard deviation; SE, standard error
* The difference in each variables was calculated by analysis of covariance with baPWV at baseline as covariate.
Table 3 Brachial-ankle pulse wave velocity (baPWV) at baseline and its changes with baPWV at baseline as covariate
according to MetS status and the number of MetS components
baPWV at baseline 3-year changes of baPWV
†
Variable at baseline n Mean ± SD Adjusted mean
±S E
p value Trend test
p value
MetS 0.001 -
No 950 1518.5 ± 373.6 -9.5 ± 7.4
Yes 568 1780.1 ± 396.6 31.1 ± 9.7
Number of MetS components < 0.001 < 0.001
0 221 1342.2 ± 203.0 -37.2 ± 15.7
1 354 1499.6 ± 380.6 -16.2 ± 12.1
2 375 1640.3 ± 399.5 10.8 ± 11.6
≥ 3 568 1780.1 ± 396.6 32.6 ± 9.8
MetS, metabolic syndrome; SD, standard deviation; SE, standard error.
†All values were calculated by analysis of covariance with baPWV at baseline as covariate.
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baPWV was 1813 cm/s. The adjusted odds of the high-
risk group with arterial stiffness for MetS were 1.52
(95% confidence interval [CI], 1.21-1.90). The adjusted
odds ratios (ORs) of the high-risk group with arterial
stiffness were 3.31 (95% CI, 2.06-5.33), 4.21 (95% CI,
2.57-6.91), and 5.24 (95% CI, 3.20-8.57) in subjects with
1, 2, and ≥ 3 MetS components after multivariate
baPWV (cm/sec)
0.0 20.0 40.0 60.0 80.0 100.0
>=3 MetS components
2 MetS components
1 MetS component
0 MetS component
N.a.N.
MetS
No MetS
36.2***
38.2***
46.7***
76.3***
Figure 1 Multivariate linear regression with the use of generalized estimating equations of longitudinal brachial-ankle pulse wave
velocity (baPWV) based on metabolic syndrome (MetS) and its number of components. Both models were adjusted for age, gender,
education, smoking status at baseline, time-dependent hypertension medication, and time-dependent mean arterial pressure. Point estimates
and standard errors of baPWV for MetS and each number of MetS components were shown as rhombic point and horizontal bar. ***p < 0.001
Table 4 Hierarchical multivariate linear regression with generalized estimating equation analysis for brachial-ankle
pulse wave velocity (baPWV) changes in 1518 subjects during a 3-year follow up
Estimate (95% CI)
MetS† components Model 1 Model 2 Model 3 Model 4 Model 5
Elevated blood pressure 32.3*
(6.2~58.3)
29.2*
(3.4~55.0)
29.8*
(4.1~55.6)
28.2*
(2.5~53.9)
28.3*
(2.5~54.0)
Elevated fasting glucose 51.6***
(31.7~71.4)
52.5***
(32.5~72.6)
51.5***
(31.5~71.5)
51.4***
(31.3~71.4)
Central obesity -9.5 (-30.9~11.9) -11.1
(-32.6~10.4)
-11.3
(-32.8~10.2)
Elevated triglyceride 20.8
(-1.8~43.4)
20.2
(-2.6~43.0)
Low HDL
† cholesterol 2.7
(-16.9~22.3)
CI, confidence interval.
† MetS, metabolic syndrome; HDL, high-density lipoprotein
All models were adjusted for age, gender, education, smoking status at baseline, time-dependent hypertension medication, and time-dependent mean arterial
pressure.
* p < 0.05, ** p < 0.01, *** p < 0.001
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adjusted OR and the number of components of MetS
was found (p for trend < 0.05). The adjusted ORs of the
high-risk group with arterial stiffness were 3.72 (95% CI,
2.81-4.93) and 1.35 (95% CI, 1.08-1.68) in individuals
with elevated blood pressure and fasting glucose (both p
< 0.05) (Figure 2).
Discussion
In this 3-year community-based prospective study, we
found that MetS and the MetS components indepen-
dently predicted the future progression or incidence of
arterial stiffness. Regarding the influence of individual
components of MetS on arterial stiffness, we found that
blood pressure and fasting glucose were independent
determinants of longitudinal arterial stiffness progres-
sion in this general population. Moreover, they were
independent risk factors for predicting the 3-year inci-
dence of the higher risk of developing arterial stiffness.
The existence of a strong association between the pre-
sence of MetS and arterial stiffness has been shown in
many cross-sectional studies [27-29]. However, the long-
itudinal effect of MetS on arterial stiffness in the general
population has not been clarified [34,35,39]. In this
longitudinal population-based study, we provided com-
munity-based evidence that MetS is an independent risk
factor for progression of arterial stiffness in a random
sample of Taiwaneses adults aged 40 years and over.
Our findings were consistent with those of several pre-
vious studies that showed a causal relationship between
MetS and arterial stiffness. In a 3-year prospective study
of 2, 080 male employees in a company, Tomiyama et
al. showed that subjects with persistent MetS had a
higher annual rate of increase in baPWV than those
with regression of MetS during the follow-up period
[34]. Similar deleterious effects of MetS on aortic stiff-
ness were found in a 6-year follow-up study of a health
check-up for 476 French adults who were working and
retired persons and their families [35].
In the present study, only elevated blood pressure and
fasting glucose were independent predictors of progres-
sive arterial stiffness. Tomiyama et al. [34], in their study
Odds ratio
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0
No MetS
MetS
0 MetS component
1 MetS component
2 MetS components
>=3 MetS components
Normal blood pressure
Elevated blood pressure
Normal fasting glucose
Elevated fasting glucose
No central obestiy
Central obesity
Normal triglyceride
Elevated triglyceride
Normal HDL cholesterol
Low HDL cholesterol
1.07
0.93
1.35
1.13
3.72
5.24
4.21
3.31
1.52
†
†
Figure 2 Multivariate-adjusted odds ratio of top quartile of brachial-ankle pulse wave velocity (baPWV) at baseline based on MetS,
number of MetS components, and individual MetS components after adjusting for age, gender, education, smoking status at
baseline, time-dependent hypertension medication, and time-dependent mean arterial pressure. The cut-off point of the top quartile of
baseline baPWV was 1813 cm/s.
† MetS, metabolic syndrome; HDL, high-density lipoprotein. * The linear trend of baPWV changes in the number
of MetS components in the top quartile was statistically significant.
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age of 3 years of follow-up, found elevated blood pressure
and fasting glucose at baseline were independent predic-
tors for changes in baPWV, which was consistent with
our findings. Li et al [39] followed 835 young adults aged
4t o1 7y e a r sw i t h2 6 . 5y e a r si na v e r a g e ,a n df o u n dt h a t
the independent predictors of baPWV in young adults
were systolic blood pressure, HDL cholesterol, and trigly-
cerides in adulthood. However, we did not find that ele-
vated triglyceride and low HDL cholesterol were
associated with longitudinal baPWV. There are two pos-
sible reasons why Li et al.’s findings [39] were not consis-
tent with ours. One is that they did not measure baPWV
at baseline and could not correct or adjust it, which may
have resulted in overestimating the effects of triglyceride
and HDL cholesterol. The other is that our study lacked
power to detect the effect of triglyceride and HDL cho-
lesterol, due to the shorter follow-up period than that in
Li et al’s study [39].
The possible mechanism that can explain the effect of
elevated blood pressure on progressive arterial stiffness is
its direct effect on arterial walls. Elevated blood pressure
may accelerate arterial stiffening because it forces
endothelial cells and arterial smooth muscle cells to be
exposed to the increase arterial wall dispensability chroni-
cally, which reflects arterial stiffening [40]. Elevated blood
glucose leads to the formation and deposition of advanced
glycation end-products, which promote the crosslinking of
collagen that stiffens the structural components of the
arterial wall [41].
This study has several strengths. First, this was a pro-
spective study; therefore, the temporal relationship
between metabolic risk factors and arterial stiffness could
be clearly ascertained. Second, this was a community-
based cohort which could be representative of the general
population. And lastly, our study evaluated arterial stiff-
ness using non-invasive and simple baPWV measure-
ment, and statistical corrections were made to prevent
the influence of blood pressure. However, there are two
limitations to our study. One is that our findings could
not be generalized to young adults because we recruited
participants aged 40 and over. The other is that the find-
ings of our study may not be generalized to adults living
in areas of less urbanization, because our sample was ran-
domly selected from a population in a metropolitan area.
Conclusions
We found that MetS and its components of fasting glu-
cose and blood pressure are independent predictors of
the longitudinal increase in arterial stiffness. Since these
predictors are associated with significant cardiovascular
morbidity and mortality, our findings suggest that man-
agement of MetS to prevent progression to advanced
arterial vascular disease is important.
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